ARGX
Argenx

1,291
Mkt Cap
$44.96B
Volume
282,611.00
52W High
$857.48
52W Low
$510.06
PE Ratio
40.15
ARGX Fundamentals
Price
$854.65
Prev Close
$851.02
Open
$856.48
50D MA
$782.86
Beta
0.59
Avg. Volume
385,965.48
EPS (Annual)
$13.89
P/B
8.58
Rev/Employee
$1.37M
Loading...
Loading...
News
all
press releases
JPMorgan Chase & Co. Increases argenex (NASDAQ:ARGX) Price Target to $925.00
JPMorgan Chase & Co. lifted their price target on shares of argenex from $830.00 to $925.00 and gave the company an "overweight" rating in a research report on Friday...
MarketBeat·10h ago
News Placeholder
More News
News Placeholder
argenex (NASDAQ:ARGX) Sets New 52-Week High - Here's What Happened
argenex (NASDAQ:ARGX) Reaches New 52-Week High - Here's Why...
MarketBeat·1d ago
News Placeholder
Halozyme Beats on Q3 Earnings & Revenues, Raises 2025 View
HALO posts strong third-quarter results with earnings and revenues topping estimates and raises 2025 guidance on robust royalty growth.
Zacks·5d ago
News Placeholder
INCY or ARGX: Which Is the Better Value Stock Right Now?
INCY vs. ARGX: Which Stock Is the Better Value Option?
Zacks·24d ago
News Placeholder
INCY vs. ARGX: Which Stock Is the Better Value Option?
INCY vs. ARGX: Which Stock Is the Better Value Option?
Zacks·1mo ago
News Placeholder
AbbVie Seeks FDA Nod for Tavapadon to Treat Parkinson's Disease
ABBV files for FDA approval of tavapadon, a once-daily oral Parkinson's drug backed by late-stage TEMPO studies.
Zacks·1mo ago
News Placeholder
Are Medical Stocks Lagging Argenx (ARGX) This Year?
Here is how argenex SE (ARGX) and Collegium Pharmaceutical (COLL) have performed compared to their sector so far this year.
Zacks·2mo ago
News Placeholder
KMDA or ARGX: Which Is the Better Value Stock Right Now?
KMDA vs. ARGX: Which Stock Is the Better Value Option?
Zacks·2mo ago
News Placeholder
15 names that Morgan Stanley’s analysts expect to move meaningfully on earnings
Investing.com -- Morgan Stanley expects a “normal” earnings beat rate for the second quarter, with S&P 500 EPS growth forecast at 5% year-over-year and sales up 4%.
investing.com·4mo ago
News Placeholder
EXEL vs. ARGX: Which Stock Should Value Investors Buy Now?
EXEL vs. ARGX: Which Stock Is the Better Value Option?
Zacks·4mo ago

Latest ARGX News

View

Advertisement|Remove ads.

Advertisement|Remove ads.